Click here for slides on this topic


Basal rate

The amount of insulin required to manage normal daily blood glucose fluctuations.
The following content matched the glossary term: Basal rate

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 11, 2012

Top

Daily coverage of American Diabetes Association 72nd Scientific Sessions  June 11, 2012

ORIGIN trial results, insulin and cancer, TINSAL-T2D results, and more.

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 10, 2012

Top

Daily coverage from the American Diabetes Association 72nd Scientific Sessions June 10, 2012

Beta-cell function preservation, ACCORD-BP, update on insulin therapies for diabetes treatment, pharmacology for diabetes prevention, and more. 

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 9, 2012

Top

Daily coverage of American Diabetes Association 72nd Scientific Sessions  June 9, 2012

Results from the EASIE, EUREXA, TODAY, and Diabetes Prevention Program (DPP) trials; new data on SGLT2 inhibitors for diabetes treatment, incretins for diabetes treatment, ATP-IV guideline update, and more.

 

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 8, 2012

Top

Daily coverage of American Diabetes Association 72nd Scientific Sessions  June 8, 2012

Diabetes and hypoglycemia, clinical management of diabetes, obesity treatment, diabetes in long-term care, and more. 

Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis

Top

Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase 4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting systematic review and meta analysis. BMJ. 2012;344:e1369. doi 10.1136 bmj.e1369. OBJECTIVE: To assess the efficacy and safety of dipeptidyl peptidase-4 (DPP-4) inhibitors compared with metformin as monotherapy, or with other commonly used hypoglycaemic drugs combined with metformin, in adults with type 2 diabetes mellitus.

Pharmacokinetics & Pharmacodynamics of Therapeutic Doses of Basal Insulins NPH, Glargine, & Detemir After 1 Wk of Daily Admin at Bedtime

Top

Lucidi P, Porcellati F, Rossetti P, Candeloro P, Cioli P, Marzotti S, Andreoli AM, Fede R, Bolli GB, Fanelli CG. Pharmacokinetics and Pharmacodynamics of Therapeutic Doses of Basal Insulins NPH, Glargine, and Detemir After 1 Week of Daily Administration at Bedtime in Type 2 Diabetic Subjects: A randomized cross-over study. Diabetes Care. 2011;34(6):1312-4. To compare the pharmacokinetics and pharmacodynamics of NPH, glargine, and detemir insulins in type 2 diabetic subjects.

DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results

Top

Buse JB, Wolffenbuttel BH, Herman WH, et al. DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results. Diabetes Care. 2009;32(6):1007-1013. OBJECTIVE: To compare the ability of two starter insulin regimens to achieve glycemic control in a large, ethnically diverse population with type 2 diabetes.

Hyperlipidemia Is Toxic to b-Cells, but Only in the Presence of Hyperglycemia

Top

Poitout V, Robertson RP. Minireview: Secondary Beta-Cell Failure in Type 2 Diabetes-A Convergence of Glucotoxicity and Lipotoxicity. Endocrinology. 2002;143:339-342. Both hyperglycemia and hyperlipidemia have been implicated as contributors to b-cell failure in type 2 diabetes. The authors of a recent review article believe that chronic hyperglycemia, by itself, is toxic to b-cells, whereas chronic hyperlipidemia is only toxic to beta-cells in the presence of hyperglycemia.

Effect of Rosiglitazone on Glucose and Non-esterified Fatty Acid Metabolism in Type II Diabetic Patients

Top

Miyazaki Y, Glass L, Triplitt C, et al. Effect of Rosiglitazone on Glucose and Non-esterified Fatty Acid Metabolism in Type II Diabetic Patients. Diabetologia. 2001;44:2210-2219. Aims/hypothesis: We aimed to examine the mechanisms by which rosiglitazone improves glycaemic control in Type II (non-insulin-dependent) diabetic patients.

Thiazolidinediones Increase Plasma-Adipose Tissue FFA Exchange Capacity and Enhance Insulin-Mediated Control of Systemic FFA Availability

Top

Oakes ND, Thalen PG, Jacinto SM, Ljung B. Thiazolidinediones Increase Plasma-Adipose Tissue FFA Exchange Capacity and Enhance Insulin-Mediated Control of Systemic FFA Availability. Diabetes. 2001;50:1158-1165. We studied the effects of thiazolidinedione treatment (rosiglitazone 1 or 10 µmol · kg-1 · day-1 or darglitazone 1.3 µmol · kg-1 · day-1 for 3 weeks) on lipid metabolism in obese Zucker rats. In the basal 7-h fasted state, rosiglitazone (10 µmol · kg-1 · day-1) and darglitazone corrected the hypertriglyceridemia by increasing plasma triglyceride (TG) clearance and decreasing hepatic TG production, as assessed using Triton WR 1339.

1 2 Next 

Slide Library Results

Search Results for: Basal rate Slides Found: 0